Menu
← Oncology Approval Tracker
FDA DECISION ·
Adstiladrin
nadofaragene firadenovec-vncg · Ferring Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
LAMPGEN ANALYSIS
Why it matters
An intravesical gene therapy expands bladder-preserving options after BCG failure for patients with carcinoma in situ.
What research teams should watch
Verify the BCG record and carcinoma in situ pathology, then coordinate administration and cystoscopic surveillance.
PRIMARY RECORDS